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Figure 1. (a) Treg suppressive units, deﬁned as (absolute Treg)/(absolute Treg capable of achieving 50% suppression of CD4+CD25- T responders with CD3/CD28
stimulus) at day 30 post-HCT, (b) cumulative incidence of grade II-IV acute GVHD, (c) meanweekly prednisone dose/kg recipient body weight among patients without
death or malignancy relapse, and (d) relapse-free survival from time of HCT
Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S345502
CD3/CD28 Co-Stimulated Activation of PI3K-mTORC2-AKT
Metabolic Programming Augments Granzyme B
Expression and Direct Cytotoxicity in Expanded Human
iNKT Cells
Ramon I. Klein-Geltink 1, Claudia A. Alves de Araujo 2,
Kelly A. Andrews 2, E. Shuyu 2, Geoff A. Neale 3,
Christopher A. Calabrese 4, Gerard Grosveld 1, Asha Pillai 5.
1 Genetics, St. Jude Children’s Research Hospital, Memphis, TN;
2 BMTCT, St. Jude Children’s Research Hospital, Memphis, TN;
3Hartwell Center for Bioinformatics and Biotechnology, St. Jude
Children’s Research Hospital, Memphis, TN; 4 Department of
Small Animal Imaging, St. Jude Children’s Research Hospital,
Memphis, TN; 5 Department of BMTCT, St Jude Children’s
Research Hospital, Memphis, TNInvariant natural killer T (iNKT) lymphocytes are rare but
potent effectors of immune regulation and tumor immuno-
surveillance. iNKT cells are MHC-non-restricted and thus
ideal candidates for separation of GVHD and GVT after either
MHC-matched or mismatched allogeneic hematopoietic celltransplantation (HCT). We have optimized a reproducible
therapeutic expansion protocol for human iNKT cells from
peripheral blood pheresis units and used this platform to
delineate targetable pathways to augment cytokine secretion
and direct cytotoxicity of expanded CD3+Va24+Vb11+ iNKT
cells against lymphoid malignancies. Expanded, anti-CD2/
CD3/CD28-stimulated iNKT cells expressed signiﬁcantly
higher (> 1500 pg/mL) levels of Th2 cytokines IL-4, IL-5, and
IL-13, and GM-CSF, and substantially higher intracellular
granzyme B (GrB) and PI3-kinase downstream phospho-AKT
(p-AKT) at both the mRNA and protein levels as compared to
iNKT cells treated with vehicle (P < 0.01), a-galactosylcer-
amide (a-GalCer) (P < 0.01), or anti-Va24 CDR3 loop stimu-
lating antibody clone 6B11 (P < 0.01) (n ¼ 4-6 serial
expansions). In vitro iNKTcytotoxicity against NALM/6 Ph+ B-
lineage acute lymphoblastic leukemia (B-ALL) was signiﬁ-
cantly augmented by CD2/CD3/CD28 activation (mean 
SEM % cytotoxicity in BADTA assay at 1:1 iNKT: target ratio
60.8  2.8, P < 0.001, n ¼ 12) but not a-GalCer stimulation
(11.5 5.0, P¼ 0.98, n¼ 12) or 6B11 treatment (11.0 4.1, P¼
0.99, n ¼ 12) as compared to vehicle control. Potent
augmentation of tumor clearance in vivo after CD2/CD3/
CD28 but not a-GalCer or 6B11 stimulation was conﬁrmed in
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25 mice/group; P < 0.001). Speciﬁc GrB inhibition by iNKT
pre-treatment with the non-competitive inhibitor Z-AAD-
CMK abrogated CD2/CD3/CD28 augmented iNKT cytotox-
icity, both in vitro and in vivo. Using permutations of CD2,
CD3, and CD28 stimulation combined with speciﬁc inhibitors
of the PI3K-AKT-mTORC pathway, we deﬁned that CD3/
CD28-co-stimulated, PI3K-downstream, mTORC2-driven
AKT activation directly up-regulates GrB protein expression
and augments GrB-dependent cytotoxicity in expanded hu-
man iNKT cells. Notably, CD2/CD3/CD28-induced augmented
iNKT killing was not inhibited by cyclosporin A, rapamycin,
or tacrolimus. These data demonstrate the novel potential for
augmentation of cytokine secretion and cytotoxicity in hu-
man iNKT cells through AKT signaling independent of
mTORC1 or NF-AT, deﬁning a key pathway for control of iNKT
effector functions with broad implications for immuno-
therapy, vaccine augmentation, and anti-infective therapies.
As our studies utilized random donor human iNKT cells
expanded using a clinically applicable protocol, these data
are directly relevant to therapeutic human iNKT cell
manipulation to separate GVHD and GVT in the peri-
transplant or non-transplant setting of human iNKT
immunotherapy.503
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Allogeneic hematopoietic cell transplantation (allo-HCT) for
hemoglobinopathies is restricted by limited matched donors
and by graft rejection and graft-versus-host disease (GVHD)
after alternative donor HCT. Based upon our clinical data in
aplastic anemia (Pillai et al, ASBMT 2011), we pre-clinically
assessed non-myeloablative Total Lymphoid Irradiation (TLI)
+ Anti-Thymocyte Serum (ATS) +/- cyclophosphamide (CTX)
vs. total body irradiation (TBI)/ATS +/- CTX in an MHC-mis-
matched BALB/c (H-2d) into HW-80 (H-2b) b-thalassemia
(HW-80 b-thal+/-) model.
Methods: Wild-type (WT) and b-thal+/- HW-80 mice
received TLI (240 cGy x 10) + ATS (TLI/ATS, n ¼ 10), +/- CTX
(200 mg/kg) (TLI/ATS/CTX, n ¼ 15), ATS/CTX alone (n ¼ 10),
or ATS/CTX with 1200 cGy, 600 cGy, or 300 cGy TBI (1200 T/
A/C, 600 T/A/C, 300 T/A/C; n ¼ 10 each), and 50 x 106 bone
marrow + 60 x 106 splenocytes (BMT) from WT BALB/c do-
nors. Survival, weekly weight, day 28 and day 100 tri-lineage
engraftment and CBC, and histopathologic GVHD were
assessed.
Results: WT HW-80 recipients of either TLI/ATS or TLI/ATS/
CTX engrafted through day 100; HW-80 b-thal+/- mice had >
40% graft rejection after TLI/ATS + BMT, but 100% graft
retention after TLI/ATS/CTX + BMT, indicating a disease-
associated engraftment barrier overcome by addition of CTX
to TLI/ATS. All engrafting b-thal+/- mice showed stable mixed
hematopoietic chimerism and day 100 hematocrit (Hct)
correction (P ¼ 0.01 vs untreated b-thal+/-). However, TLI/
ATS/CTX recipients had no GVHD, whereas engrafting TLI/
ATS mice developed lethal GVHD by day 100 [cumulative
scores: TLI/ATS/CTX: 0.3 +/- 0.2; TLI/ATS: 6.8 +/- 0.9; P <
0.01]. 100% of 1200 T/A/C, 60% of 600 T/A/C, and 40% of 300 T/A/C mice engrafted. In all T/A/C groups, > 80% engrafters had
lethal GVHD, whereas > 70% of 100-day survivors showed
non-engraftment. We delineated that recipient regulatory
MDSC induce tolerance via MHC-independent in vivo
expansion of donor Foxp3+ nTreg after TLI/ATS + BMT (van
der Merwe et al, J Immunol 2013). We found signiﬁcant (P <
0.001) increase in recipient CD11b+Gr-1(G)hi MDSC in TLI/
ATS/CTX- versus TLI/ATS-conditioned b-thal+/- mice, with
increased number (P < 0.01) and proliferation (P < 0.05) of
donor Foxp3+ nTreg and decreased CD8+ T cell number and
proliferation (P < 0.01) in spleens at day 6. In adoptive
transfers, TLI/ATS/CTX-derived recipient CD11b+Gr-1Ghi
MDSC regulated otherwise lethal GVHD through day 100
post-BMT in 1200 cGy TBI-conditioned WT B6 recipients of
WT BALB/c BMT. Our data indicate that TLI/ATS/CTX facili-
tates robust recipient <–> donor tolerance, provide pre-
clinical support for application of TLI/ATS/CTX prior to
(potentially MHC-mismatched/haploidentical) allo-HCT for
hemoglobinopathies, and give the ﬁrst direct evidence for an
innate immune mechanism of alkylator-associated trans-
plantation tolerance, which we propose to validate in the
context of a clinical trial.504
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Introduction: While DCBT has been associated with high
PFS in both children & adults, rates of grade II-IV aGVHD are
signiﬁcant in patients transplanted with calcineurin inhibi-
tor/ mycophenolate mofetil (CNI/MMF) immunosuppression
(IS) without anti-thymocyte globulin. However, GVHD
biology in DCBT recipients appears distinct from that of adult
donor allografts with a high incidence of corticosteroid
responsiveness & low rates of chronic GVHD. Consequently,
the impact of aGVHD upon long-term PFS in DCBT may be
different to that of adult donor allografts & is not established.
Methods: We analyzed the time to systemic (sys.) IS cessa-
tion, transplant-related mortality (TRM), relapse, & PFS in a
day 100 landmark analysis of DCBT recipients transplanted
for hematologic malignancies who were engrafted &
progression-free according to the incidence & severity of
their aGVHD by day 100.
Results: 129 day 100 progression-free DCBT survivors (me-
dian age 36 years, range 0.9-70) were evaluated. Of this
cohort, 80 (62%) had grade II-IV aGVHD (55 grade II, 21 grade
III, & 4 grade IV disease), & all 129 patients were on sys.IS at
day 100.With a median follow-up of 4.8 years (range 1.2-9.0)
in this cohort, the cumulative incidence of achieving sus-
tained sys.IS cessation was 33% (95%CI: 25-42) at 1-year, 55%
(95%CI: 45-63) at 2-years, & 61% (95%CI: 51-69) at 3-years
